MedTrace Logo

Effect of Wet Cupping Versus Moderate Intensity Aerobic Exercise on Inflammatory Markers in Diabetic Patients

NCT06667648 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-07

No results posted yet for this study

Summary

Among all pro-inflammatory biomarkers, TNF-α first recognized to be involved in the pathenogenesis of insulin resistance, and glucose-related abnormalities that link to T2DM. TNF-α plays a vital role in the overall pathophysiology of insulin resistance especially in males with greater body mass index as compared to that in the females This trial aims to investigate the effect of wet cupping therapy versus moderate intensity aerobic exercise on inflammatory markers in diabetic patients

Conditions

Interventions

PROCEDURE

cupping session

Each cupping session takes about 30-40 min and can be conducted in five steps. The first step includes primary suction. In this phase, the therapist allocates specific points or areas for cupping and disinfects the area, which located at the upper back (opposite to C7), Para spinal and below scapula. A cup with a suitable size is placed on the selected site and sucked the air inside the cup by manual suction. Then the cup was applied to the skin and left for a period of 3 to 5 min. The second step is about puncturing. Puncturing with a needle to get out of blood the third step is about suction and bloodletting. The cup is placed back on the skin using the similar procedure described above for 3 to 5 min. The fourth step includes the removal of the cup, followed by the fifth step which includes dressing the area after cleaning and disinfecting with FDA-approved skin disinfectant.

Sponsors & Collaborators

  • Deraya University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-15
Primary Completion
2024-09-11
Completion
2024-10-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667648 on ClinicalTrials.gov